Edesa Biotech, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended March 31, 2020; filed May 15, 2020. The company’s fiscal year ends September 30. Amounts are in U.S. dollars.
Business context
Edesa is a clinical-stage biopharmaceutical company developing treatments for dermatological and gastrointestinal conditions. Its lead candidate, EB01, is in a Phase 2B study for allergic contact dermatitis; EB02 is being studied for hemorrhoidal disease. The reported revenue came from sales of product inventory acquired in the June 2019 reverse acquisition, not from its clinical candidates.
Key financial results
| Metric | Three months ended March 31, 2020 | Six months ended March 31, 2020 | Six months ended March 31, 2019 |
|---|---|---|---|
| Revenue | $110,516 | $218,316 | $0 |
| Research and development | $502,814 | $1,030,812 | $369,093 |
| General and administrative | $1,113,917 | $1,795,623 | $577,426 |
| Operating loss | $1,516,252 | $2,621,934 | $946,519 |
| Net loss | $1,489,636 | $2,583,969 | $893,679 |
| Basic and diluted loss per share | $0.17 | $0.32 | $0.28 |
- Six-month operating cash use was $1.96 million, compared with $781,228 a year earlier. Investing activities provided $42,359; financing activities provided $3.89 million, net of issuance costs.
- Cash and cash equivalents were $6.99 million at March 31, 2020, up from $5.03 million at September 30, 2019. Working capital was $6.85 million; shareholders’ equity was $6.93 million.
- Total liabilities were $701,681, including $185,439 of operating lease liabilities. The filing reports no borrowings or other debt.
- Product sales and services had a six-month gross profit of $204,501 (revenue less cost of sales of $13,815); this relates to acquired inventory and is not indicative of recurring candidate revenue.
Changes versus the prior comparable period
- Six-month net loss increased to $2.58 million from $893,679. R&D rose by about $662,000, primarily due to EB01 clinical study activity and personnel costs. General and administrative expense rose by about $1.22 million, reflecting personnel, legal and professional fees, and public-company costs.
- The January 2020 registered direct offering and concurrent warrant placement raised $4.36 million gross and approximately $3.89 million net. The offering issued 1,354,691 common shares; common shares outstanding were 8,859,159 at March 31 and May 13, 2020.
- Comparability is limited: 2019 periods before the June 7, 2019 reverse acquisition reflect Edesa Biotech Research on a standalone basis.
Outlook, risks, and unusual items
- Management said it planned to fund operations for the next 12 months using cash on hand, while noting it may seek additional equity, grants, debt, licensing, or other financing. It cautioned that funding may not be available on acceptable terms, particularly amid COVID-19 market disruption.
- COVID-19 temporarily paused new patient randomization at several EB01 study sites. The company amended the protocol to allow remote visits and simplify procedures; it said the blinded interim readout would likely occur later than originally anticipated, while the ultimate timeline impact remained unclear.
- On April 17, 2020, after quarter-end, Edesa licensed monoclonal antibodies targeting TLR4 and CXCL10. Consideration included $2.5 million of newly designated Series A-1 convertible preferred shares, milestone payments of up to $363.5 million, and royalties or sublicensing payments. Edesa also agreed to buy TLR4 antibody inventory for $5.0 million in two installments. These are subsequent events, not March 31 balance-sheet amounts.
- Existing clinical and license commitments included approximately $1.784 million of contracted research and other service payments and milestone obligations of up to $18.6 million and $18.5 million under two earlier licenses. Milestones are contingent on achievement of specified events.
- The company identified unhedged Canadian-dollar exposure: a 10% annual exchange-rate change was estimated to affect loss and other comprehensive loss by approximately $247,000. Management reported effective disclosure controls and no material change in internal control over financial reporting. No material legal proceedings or material risk-factor changes were reported in this filing.
Important facts for investors to verify
- Whether COVID-related site interruptions delay EB01 enrollment, interim results, or study completion.
- How cash use, clinical spending, and the April 2020 license and $5.0 million inventory purchase affect liquidity and the stated 12-month funding plan.
- The terms and potential dilution from the Series A-1 preferred shares and outstanding warrants, including exercise timing and prices.
- The timing and likelihood of contingent milestone payments under the company’s license agreements; maximum stated obligations are not necessarily current or payable amounts.
- Whether the small inventory-related revenue recurs; the filing says the company had not generated revenue from its product candidates.